Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir and Daclatasvir in HCV Genotype 1b or 4 with Renal Impairment
NCT02397395Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Virologic Response at Week 12 After End of Treatment. Planned start May 2015; status: withdrawn.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02397395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397395.